Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company focused on harnessing the immune system to achieve deep and durable responses for patients with cancer. The company utilizes its proprietary tumor-activation platform to design novel immuno-oncology (I-O) therapies, including cytokines and checkpoint inhibitors, that are intended to be localized and active only within the tumor microenvironment. By engineering therapies that remain inactive in peripheral circulation and activate specifically in the tumor, Xilio aims to minimize systemic toxicities and maximize the therapeutic index of potent I-O agents. Their approach addresses the historical limitations of cytokines and antibodies that have been restricted by severe side effects when administered systemically.